LONDON, 03-Mar-2017 — /EuropaWire/ — MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division…
Qtern fixed-dose combination will provide an additional oral medicine option for patients taking Farxiga (dapagliflozin) to improve blood sugar level…
STOCKHOLM, 27-Sep-2016 — /EuropaWire/ — New understanding of how hormone-producing cells in the pancreas decode their genetic instructions is pointing to…
LONDON, 02-May-2016 — /EuropaWire/ — AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…
Missed primary efficacy endpoint; fewer events observed in the Brilinta arm but trend did not reach statistical significance Consistent safety…
LONDON, 10-12-2015 — /EuropaWire/ — AstraZeneca today announced plans to test a digital support service for women undergoing treatment for…
LONDON, 31-8-2015 — /EuropaWire/ — Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at…
Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®(vandetanib) from AstraZeneca Paris, France, 30-7-2015 — /EuropaWire/ — Sanofi and…
LONDON, 2-6-2015 — /EuropaWire/ — AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results…
LONDON, 4-5-2015 — /EuropaWire/ — AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental…
Phase II/III trial of AZD3293, an oral potent small molecule inhibitor of BACE, aims to enrol more than 1,500 patients…
LONDON, 2-12-2014 — /EuropaWire/ — AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted for filing…
LONDON, 11-11-2014 — /EuropaWire/ — AstraZeneca, with its global biologics research and development arm, MedImmune, will present new data from…
Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International Congress LONDON, 8-9-2014 — /EuropaWire/…
London, UK, 03-6-2014 — /EuropaWire/ — AstraZeneca today announced that the US Food and Drug Administration (FDA) has designated its novel investigational…
London, UK, 03-6-2014 — /EuropaWire/ — AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for…
London, UK, 25-4-2014 — /EuropaWire/ — Pascal Soriot, Chief Executive Officer, commenting on the results, said: “The first quarter has seen continued…
Karolinska Institutet has appointed Professor Bo Angelin to lead the Integrated Cardio Metabolic Centre (ICMC), a joint initiative with AstraZeneca.…
London, United Kingdom, 10-10-2013 — /EuropaWire/ — AstraZeneca today announced that on 4 October MedImmune, its global biologics research and development arm,…
London, United Kingdom, 10-10-2013 — /EuropaWire/ — AstraZeneca today announced that the US Court of Appeals for the Federal Circuit (CAFC) lifted…
16-7-2013 — /europawire.eu/ — AstraZeneca today announced that it has entered into an agreement with the University of Cambridge and Cancer…
16-7-2013 — /europawire.eu/ — AstraZeneca today announced that Simon Lowth, Chief Financial Officer (CFO) and Executive Director, will leave the company…
28-6-2013 — /europawire.eu/ — AstraZeneca today announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics, a privately held…
25-6-2013 — /europawire.eu/ — AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have…
Move brings AstraZeneca’s small molecule and MedImmune’s biologics research and development together at purpose-built facility on Cambridge Biomedical Campus 21-6-2013…
20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular…